- Markets
- Chemicals
- ROSSARI
ROSSARI
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Rossari Biotech Says Appellate Body Allows Unit's Appeal, Sets Aside Tax Order
Feb 20 (Reuters) - Rossari Biotech Ltd ROSB.NS:
APPELLATE BODY ALLOWS UNIT'S APPEAL, SETS ASIDE TAX ORDER
Source text: ID:nBSE3z6hxt
Further company coverage: ROSB.NS
(([email protected];;))
Feb 20 (Reuters) - Rossari Biotech Ltd ROSB.NS:
APPELLATE BODY ALLOWS UNIT'S APPEAL, SETS ASIDE TAX ORDER
Source text: ID:nBSE3z6hxt
Further company coverage: ROSB.NS
(([email protected];;))
India's Rossari Biotech slides on Q3 profit fall
** Rossari Biotech ROSB.NS falls as much as 5.8% to 755.7 rupees; last down 4.1%
** Specialty chemicals maker's Q3 consol net profit drops 7.8% y/y
** Stock moved below its 100-day and 200-day simple moving avgs after result
** More than 82,000 shares traded, 1.4x its 30-day avg
** Stock rated "strong buy" on avg; median PT is 1,004 rupees, ~30.4% higher than current price - LSEG
** ROSB fell 2.8% in 2024
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
** Rossari Biotech ROSB.NS falls as much as 5.8% to 755.7 rupees; last down 4.1%
** Specialty chemicals maker's Q3 consol net profit drops 7.8% y/y
** Stock moved below its 100-day and 200-day simple moving avgs after result
** More than 82,000 shares traded, 1.4x its 30-day avg
** Stock rated "strong buy" on avg; median PT is 1,004 rupees, ~30.4% higher than current price - LSEG
** ROSB fell 2.8% in 2024
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
Rossari Biotech Dec-Qtr Consol Net Profit 317 Mln Rupees
Jan 21 (Reuters) - Rossari Biotech Ltd ROSB.NS:
ROSSARI BIOTECH LTD DEC-QUARTER CONSOL NET PROFIT 317 MILLION RUPEES
ROSSARI BIOTECH LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.13 BILLION RUPEES
Source text: ID:nNSE2yvZDG
Further company coverage: ROSB.NS
(([email protected];;))
Jan 21 (Reuters) - Rossari Biotech Ltd ROSB.NS:
ROSSARI BIOTECH LTD DEC-QUARTER CONSOL NET PROFIT 317 MILLION RUPEES
ROSSARI BIOTECH LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.13 BILLION RUPEES
Source text: ID:nNSE2yvZDG
Further company coverage: ROSB.NS
(([email protected];;))
Rossari Biotech Unit Completes Acquisition Of 100% Stake In Unistar Thai Co
Dec 11 (Reuters) - Rossari Biotech Ltd ROSB.NS:
ROSSARI BIOTECH - UNIT COMPLETED ACQUISITION OF 100% STAKE IN UNISTAR THAI CO
Source text: ID:nBSE1HFKv7
Further company coverage: ROSB.NS
(([email protected];;))
Dec 11 (Reuters) - Rossari Biotech Ltd ROSB.NS:
ROSSARI BIOTECH - UNIT COMPLETED ACQUISITION OF 100% STAKE IN UNISTAR THAI CO
Source text: ID:nBSE1HFKv7
Further company coverage: ROSB.NS
(([email protected];;))
Rossari Biotech Re-Appoints Sunil Chari As MD
April 29 (Reuters) - Rossari Biotech Ltd ROSB.NS:
RE-APPOINTMENT OF SUNIL CHARI AS MD
ROSSARI BIOTECH MARCH-QUARTER CONSOL NET PROFIT 341.3 MILLION RUPEES VERSUS PROFIT 289.8 MILLION RUPEES
ROSSARI BIOTECH MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 4.73 BILLION RUPEES VERSUS 4.06 BILLION RUPEES
Further company coverage: ROSB.NS
(([email protected];;))
April 29 (Reuters) - Rossari Biotech Ltd ROSB.NS:
RE-APPOINTMENT OF SUNIL CHARI AS MD
ROSSARI BIOTECH MARCH-QUARTER CONSOL NET PROFIT 341.3 MILLION RUPEES VERSUS PROFIT 289.8 MILLION RUPEES
ROSSARI BIOTECH MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 4.73 BILLION RUPEES VERSUS 4.06 BILLION RUPEES
Further company coverage: ROSB.NS
(([email protected];;))
India's Rossari Biotech up nearly 8% to hit 6-mth high
** Shares of specialty chemicals co Rossari Biotech Ltd ROSB.NS rise as much as 7.78% to 819.90 rupees, hitting highest level since Dec. 5, 2022
** Stock on track for a third consecutive session of gain if trends hold
** Share price above 50-day, 100-day and 200-day simple moving averages, suggesting bullish trend
** ROSB's relative strength index above 70, indicating it is overbought
** More than 923,000 shares change hands by 9:57 a.m. IST, 7.2x 30-day avg of 127,650 shares
** Three analysts covering the stock have a "buy", "strong buy" and "hold" rating; median PT is 780 rupees - Refinitiv data
** Stock up 4.6% YTD, as of last close
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
** Shares of specialty chemicals co Rossari Biotech Ltd ROSB.NS rise as much as 7.78% to 819.90 rupees, hitting highest level since Dec. 5, 2022
** Stock on track for a third consecutive session of gain if trends hold
** Share price above 50-day, 100-day and 200-day simple moving averages, suggesting bullish trend
** ROSB's relative strength index above 70, indicating it is overbought
** More than 923,000 shares change hands by 9:57 a.m. IST, 7.2x 30-day avg of 127,650 shares
** Three analysts covering the stock have a "buy", "strong buy" and "hold" rating; median PT is 780 rupees - Refinitiv data
** Stock up 4.6% YTD, as of last close
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
India's Rossari Biotech gains 7% on rise in March quarter earnings
** Shares of Rossari Biotech Ltd ROSB.NS rise as much as 7.14% to 735.85 rupees, their highest in three weeks
** Rise comes after specialty chemicals maker reports 20.3% YoY growth in consolidated profit to 289.79 mln rupees in March quarter
** Core profit rises over 4% YoY to 545.81 mln rupees
** Trading volume is 274,689 shares as of 10:07 a.m. IST, 0.8x the 30-day avg - Refinitiv data
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
** Shares of Rossari Biotech Ltd ROSB.NS rise as much as 7.14% to 735.85 rupees, their highest in three weeks
** Rise comes after specialty chemicals maker reports 20.3% YoY growth in consolidated profit to 289.79 mln rupees in March quarter
** Core profit rises over 4% YoY to 545.81 mln rupees
** Trading volume is 274,689 shares as of 10:07 a.m. IST, 0.8x the 30-day avg - Refinitiv data
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
Upcoming Events:
Quarterly Results
Events:
Dividend
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Rossari Biotech do?
Rossari Biotech Limited is a top specialty chemicals manufacturer in India, providing tailored solutions for FMCG, apparel, poultry, and animal feed industries with a wide product range encompassing home care, personal care, performance and textile specialty chemicals, as well as animal health products.
Who are the competitors of Rossari Biotech?
Rossari Biotech major competitors are SH Kelkar & Co, Oriental Aromatics, Dynemic Products, Privi Speciality Che, Jocil, Clean Science, Atul. Market Cap of Rossari Biotech is ₹3,827 Crs. While the median market cap of its peers are ₹2,932 Crs.
Is Rossari Biotech financially stable compared to its competitors?
Rossari Biotech seems to be less financially stable compared to its competitors. Altman Z score of Rossari Biotech is 5.33 and is ranked 4 out of its 8 competitors.
Does Rossari Biotech pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Rossari Biotech latest dividend payout ratio is 2.11% and 3yr average dividend payout ratio is 2.5%
How has Rossari Biotech allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory
How strong is Rossari Biotech balance sheet?
Balance sheet of Rossari Biotech is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Rossari Biotech improving?
Yes, profit is increasing. The profit of Rossari Biotech is ₹135 Crs for TTM, ₹131 Crs for Mar 2024 and ₹107 Crs for Mar 2023.
Is the debt of Rossari Biotech increasing or decreasing?
Yes, The debt of Rossari Biotech is increasing. Latest debt of Rossari Biotech is ₹116 Crs as of Sep-24. This is greater than Mar-24 when it was ₹45.81 Crs.
Is Rossari Biotech stock expensive?
Rossari Biotech is not expensive. Latest PE of Rossari Biotech is 28.13, while 3 year average PE is 49.85. Also latest EV/EBITDA of Rossari Biotech is 15.21 while 3yr average is 27.28.
Has the share price of Rossari Biotech grown faster than its competition?
Rossari Biotech has given better returns compared to its competitors. Rossari Biotech has grown at ~-9.76% over the last 3yrs while peers have grown at a median rate of -15.09%
Is the promoter bullish about Rossari Biotech?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Rossari Biotech is 68.18% and last quarter promoter holding is 68.19%
Are mutual funds buying/selling Rossari Biotech?
The mutual fund holding of Rossari Biotech is increasing. The current mutual fund holding in Rossari Biotech is 13.29% while previous quarter holding is 13.25%.